Results 241 to 250 of about 2,009,855 (385)

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

Molecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea   +9 more
wiley   +1 more source

Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation.

, 1986
Hironobu Sunada, Bruce E. Magun, John Mendelsohn, Carol L. MacLeod   +3 more
openalex   +1 more source

Nuclear epidermal growth factor receptor (nEGFR) in clinical treatment. [PDF]

Heliyon
Zhu J, Wu Z, Shan G, Huang Y, Liang J, Zhan C.   +5 more
europepmc   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Biosynthesis of the epidermal growth factor receptor in human squamous cell carcinoma lines: Secretion of the truncated receptor is not common to epidermal growth factor receptor-hyperproducing cells.

, 1988
Shinobu Gamou, Masamichi Hirai, Koichi Rikimaru, Shoji ENOMOTO, Nobuyoshi Shimizu   +4 more
openalex   +2 more sources

A mutant epidermal growth factor receptor with defective protein tyrosine kinase is unable to stimulate proto-oncogene expression and DNA synthesis. [PDF]

, 1987
Annemarie Honegger, Daniele Szapary, Albrecht Schmidt, R. Lyall, E Van Obberghen, Thomas J. Dull, A Ullrich, Joseph Schlessinger   +7 more
openalex   +1 more source

Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies. [PDF]

Cancers (Basel)
Stanzione B, Del Conte A, Bertoli E, De Carlo E, Bortolot M, Torresan S, Spina M, Bearz A.   +7 more
europepmc   +1 more source

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source

Characterization of the binding properties and retrograde axonal transport of a monoclonal antibody directed against the rat nerve growth factor receptor. [PDF]

, 1985
Megumi Taniuchi, E. Marshall Johnson
openalex   +1 more source

The Drosophila epidermal growth factor receptor pathway regulates Hedgehog signalling and cytoneme behaviour. [PDF]

Nat Commun
Lalioti VS, Gradilla AC, Jiménez-Jiménez C, Fernández-Pardo C, Sánchez-Hernández D, Aguirre-Tamaral A, Sánchez-Platero I, Jordán-Àlvarez S, Wakefield JG, Guerrero I.   +9 more
europepmc   +1 more source